2008 Update: http://tinyurl.com/4 yj898
Dr. Morie Gertz provides an introduction to multiple myeloma, a cancer of the bone marrow, for the newly-diagnosed patient. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
Dr. Bill Bensinger provides an update on stem cell tranplantation in multiple myeloma from the 2007 ASCO meeting. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
Dr. Vincent Rajkimar provides an update on a trial of Revlimid with dexamethasone in multiple myeloma at the 2007 ASCO meeting. This trial concluded that lower doses of dex produced superior results. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
Dr. Gareth Morgan discusses the genetic contribution to the etiology of Thalidomide-associat ed Venous Thrombotic Events (VTEs) in multiple myeloma at the 2006 ASH meeting. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
Dr. Joan Blade discusses tandem transplants in relapsed refractory multiple myeloma at the 2007 ASCO meeting. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
Dr. Jean-Luc Harousseau discusses results of a trial comparing VAD with Velcade plus dexamethasone as indcution therapy in newly-diagnosed high-risk multiple myeloma at the 2006 ASH meeting. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
"This has been a great ASH for myeloma patients, so much new data has been presented."
Dr. Brian Durie
This overview of the 2007 American Society of Hematology Annual Meeting is provided by the International Myeloma Foundation (http://www.myeloma. org)
Dr. Antonio Palumbo discusses results of a trial of Velcade, Thalidomide with Melphalan plus Prednisone in relapsed multiple myeloma at the 2006 ASH meeting. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
Dr. Angela Dispenzieri discusses results of a Phase II trial of Revlimid/Dexamethaso ne in primary systemic amyloidosis at the 2006 ASH meeting. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
Dr. Morie Gertz discusses research presented at the 2006 meeting of the American Society of Hematology about multiple myeloma, a cancer of the bone marrow. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
Dr. Keith Stewart provides an update on trials of a new proteosome inhibitor (carfilzomib) in multiple myeloma from the 2007 ASCO meeting. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
Dr. Ruben Niesvizky discusses potential role of renal insuffieciciency in patients treated with the Biaxin Revlimid and Dexamethasone (BIRD) protocol multiple myeloma at the 2006 ASH meeting. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
Dr. Martha Lacy discusses results of a Phase II trial of Revlimid/Dexamethaso ne in relapsed refractory multiple myeloma at the 2006 ASH meeting. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
During the last decade scientists mapped the human genome providing a bridge to understanding human DNA. During the first decade of this century the International Myeloma Foundation (http://www.myeloma. org)is crossing that bridge by pioneering the first global myeloma-specific DNA bank in history: BANK ON A CUREŽ.
Dr. Jean-Luc Harousseau provides an update on trials Velcade with pegolated doxirubucin in multiple myeloma at the 2007 ASCO meeting. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
"I have personally seen more advance in the last ten years than I have in the previous three and a half decades."
Dr. Robert Kyle
This overview of the 2007 American Society Of Hematology Annual Meeting is provided by the International Myeloma Foundation (http://www.myeloma. org)
Dr. Angela Dispenzieri discusses results of trial using Velcade in patients with newly-diagnosed high-risk multiple myeloma at the 2006 ASH meeting. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
"At ASH, we had numberous presentations showing that combinations using novel agents are allowing us to achieve very high complete remission rates and is changing the treatment options for newly-diagnosed patients."
Dr. Sundar Jagannath
This video provided by the International Myeloma Foundation (http://www.myeloma. org)
Dr. Antonio Palumbo discusses results of a Revlimid with Melphalan plus prednisone in newly-diagnosed multiple myeloma at the 2006 ASH meeting. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
Former NFL lineman and Myeloma Survivor Elijah Alexander shares his reactions on attending the American Society Of Hematology Annual Meeting for the first time.
This video provided by the International Myeloma Foundation (http://www.myeloma. org)
Lifeline for the Old is a wonderful place in Jerusalem where over 270 elderly people are employed in ten workshops making beautiful Judaica and gifts. Lifeline also provides a broad array of social and health care services to the elderly. Learn more about this beautiful story by viewing this video.
Dr. Chanan Khan discusses results of a Phase II trial of Revlimid/Dexamethaso ne in relapsed refractory multiple myeloma at the 2006 ASH meeting. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
Dr. Sundar Jagannath discusses results of a Velcade with dexamethasone in newly-diagnosed multiple myeloma at the 2006 ASH meeting. For more information, contact the International Myeloma Foundation, http://www.myeloma.o rg, theimf@myeloma.org, 800-452-2873 or 818-487-7455
![What is multiple myeloma? (Int\](http://img.youtube.com/vi/XqMzT7j2k9U/2.jpg "What is multiple myeloma? (Int\")
